Skip to main content
Loading

Caledon Bioscience Inc.

October 17, 2023
Franciscan B
Multiple Therapeutics
Company Description: Caledon Bioscience is a newly formed, privately held, spin-out. We are a development stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptors, or GPCR, pathways. Caledon Bioscience is designing proprietary novel small molecule therapeutic candidates with the intent of developing best/first in class therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using our integrated drug discovery platform, medicinal chemistry expertise and deep understanding of the GPCR biology. Caledon Bioscience has active business operations in Canada and the United Kingdom.
Speakers
Bruce Pritchard, CEO - Caledon Bioscience Inc.

State

Quebec

Country

Canada

Website

http://Currently under construction - www.caledonbio.com

CEO/Top Company Official

Mr. Bruce Pritchard, BA, CA, FioD

Lead Product in Development

Our lead product in development is our GPR84 Antagonist program. Our CTA has been submitted and our Phase 1 clinical trial is expected to commence before the end of 2023.

Development Phase of Primary Product

Phase I

Number Of Unlicensed Products

3 programs

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS